Bibliography
- Rapp E, Pater JL, Willan A, Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer–report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6(4):633-41
- Crino L, Tonato M, Darwish S, A randomized trial for three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990;26(1):52-6
- Ettinger DS, Akerley W, Bepler G, Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801
- Scagliotti GV, De Marinis F, Rinaldi M, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20(21):4285-91
- Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
- Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
- Reck M, von Pawel J, Zatloukal P, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
- Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
- Di Lorenzo G, Porta C, Bellmunt J, Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526-40
- Hang XF, Xu WS, Wang JX, Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011;67(6):613-23
- Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305(5):487-94
- Correale P, Remondo C, Carbone SF, Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010;9(9):685-93
- Correale P, Botta C, Basile A. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2011;12(2):112-18
- Leon L, Vázquez S, Gracia JM, First line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small-cell lung cancer chemo-naïve patients. Expert Opin Pharmacother 2012;13(10):1389-96
- Dediu M. Should we discard vinorelbine plus cisplatin from the first-line therapy of advanced non-small-cell lung cancer? J Clin Oncol 2004;22(7):1345-7; author reply 1347